Stocksigma LogoStocksigma Logo

Natco Pharma Approves Rights Issue Up to ₹1,300 Crore and Scheme Modifications

Natco Pharma's Board approved a rights issue of equity shares (face value ₹2 each) aggregating up to ₹1,300 crore on 9th Sep'26, alongside approving the

Natco Pharma Approves Rights Issue Up to ₹1,300 Crore and Scheme Modifications

Natco Pharma Ltd · Outcome · 09 Sept 2026, 5:17 pm

Natco Pharma Approves Rights Issue Up to ₹1,300 Crore and Scheme Modifications Natco Pharma's Board approved a rights issue of equity shares (face value ₹2 each) aggregating up to ₹1,300 crore on 9th Sep'26, alongside approving the Draft Letter of Offer and forming a Fund-Raising Committee. The capital expansion will alter the company's shareholding pattern, prompting corresponding revisions to its demerger scheme with Natco Crop Health Sciences to maintain the proposed share swap ratio. Revised scheme filings will be submitted to stock exchanges following the completion of the rights issue prior to NCLT filing.

Original exchange filing (PDF)

More announcements from Natco Pharma Ltd

All Natco Pharma Ltd announcements